Group 1 - The core point of the article is that Jinbo Bio has received approval from the China Securities Regulatory Commission (CSRC) for a targeted stock issuance, marking the first such approval for the Beijing Stock Exchange in 2024, which is expected to enhance the refinancing system for companies listed on the exchange [1][4] - Jinbo Bio plans to issue up to 7.1757 million shares, aiming to raise a total of no more than 2 billion yuan, with the funds primarily directed towards the development of an AI-driven collagen database and product development platform [2][3] - The introduction of Yangshengtang as a strategic investor is expected to help Jinbo Bio overcome development bottlenecks and stimulate the upstream and downstream enterprises in the industry chain [2] Group 2 - The Beijing Stock Exchange has established a flexible and diverse refinancing mechanism since its inception, primarily utilizing methods such as private placements and convertible bonds, with Jinbo Bio's project being a significant breakthrough in the past two years [4] - The successful implementation of Jinbo Bio's stock issuance is anticipated to enhance overall market attention towards companies on the Beijing Stock Exchange, attracting various long-term funds and improving market liquidity and investor returns [5] - This project is expected to provide replicable and referable practical experience for future refinancing efforts on the Beijing Stock Exchange, aligning with its core mission to serve innovative small and medium-sized enterprises [5]

Core Viewpoint - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. plans to increase its investment in its wholly-owned subsidiary, Jinbo Medical, by 165 million yuan to support strategic development and business needs [1] Group 1: Investment Details - The registered capital of Jinbo Medical will increase from 35 million yuan to 200 million yuan following the capital increase [1] - The funding for this capital increase will come from the company's own funds and loans from new policy-based financial instruments, with no new shareholders involved [1] Group 2: Subsidiary Overview - Jinbo Medical, established on January 31, 2023, is located in Daxing District, Beijing, and its business scope includes the production of cosmetics, sanitary products, disposable medical supplies, and Class III medical devices [1] - As of September 30, 2025, Jinbo Medical's unaudited total assets are approximately 99.08 million yuan, with net assets around 30.60 million yuan [1] Group 3: Project Information - Jinbo Medical is the main entity for implementing the "Humanized Collagen FAST Database and Product Development Platform Project" of Jinbo Biological, which is currently under construction and has not yet generated operating income [1]